Literature DB >> 2452959

Studies on peripheral nerve and lens in long-term experimental diabetes: effects of the aldose reductase inhibitor statil.

G B Willars1, J Townsend, D R Tomlinson, A M Compton, R D Churchill.   

Abstract

This study determined the axonal transport of choline acetyltransferase (ChAT) activity and its content in several tissues in nondiabetic control rats and in four groups of rats with streptozotocin-induced diabetes of 6-months duration. Diabetic rats were either untreated, treated only with either the aldose reductase inhibitor Statil (Imperial Chemical Industries, Pharmaceuticals Division, Macclesfield, UK) or insulin, or were given the two in combination. Insulin treatment consisted of a single weekly injection of a long-acting insulin, a regime designed not to control the diabetes, but to provide regular respite from the catabolic dominance of uncontrolled diabetes. Elevated levels of sugars and polyols in the sciatic nerves of untreated diabetic animals were markedly attenuated by Statil. The reduced myo-inositol content and reduced axonal transport of ChAT activity also seen in these nerves were prevented by Statil, but a reduced motor nerve conduction velocity was attenuated only by Statil and insulin in combination. The presence of cataracts in all diabetic animals was associated with hyperhydration of the lens. The level of hydration and presence of cataracts were reduced by Statil, particularly in combination with insulin. ChAT activities of the iris, adrenal gland, and superior cervical ganglion were similar in all groups. Skeletal muscles showed wasting while the ileum showed an increased weight per unit length in diabetic rats. These tissues also displayed alterations in ChAT activities, particularly when referenced to unit weight of tissue, which may have been a consequence of the weight changes rather than diabetes per se.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452959     DOI: 10.1016/0026-0495(88)90044-3

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats.

Authors:  P B Inskeep; A E Reed; R A Ronfeld
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

2.  Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.

Authors:  N E Cameron; M A Cotter
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

3.  Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.

Authors:  N E Cameron; M A Cotter; K C Dines; E K Maxfield; F Carey; D J Mirrlees
Journal:  Diabetologia       Date:  1994-07       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.